---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-028208"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:17:02.936843+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagonist reports Q4 profit, $300M Takeda deal extends cash runway through 2027

## Summary
- Entered worldwide Takeda collaboration for rusfertide; $300M upfront, US profit share, opt-out up to $400M.
- Q4 net income $27.3M ($0.45 EPS) vs loss $34.2M in Q4 2022; full year loss $79M improved from $127.4M.
- Cash $341.6M; runway extended through Q4 2027 including $300M Takeda upfront.
- Earned $60M in JNJ-2113 milestones from J&J in Q4; VERIFY Phase 3 enrollment on track for Q1 2024.

## SEC filing metadata
- accession: 0001104659-24-028208
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924028208/0001104659-24-028208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924028208/tm247315d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-028208
- JSON: https://secwatch.observer/filing/0001104659-24-028208.json
- Plain text: https://secwatch.observer/filing/0001104659-24-028208.txt

## Key facts
- Earnings Releases
  Protagonist Therapeutics, Inc reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024, Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465924028208/0001104659-24-028208-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.